No abstract available.
Budesonide* ; Humans

The aim of this study was to investigate relationships between acute exacerbation and Forced Expiratory Volume 1 second (FEV1) improvement after treatment with combined long-acting beta-agonist (LABA) and inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD). A total of 137 COPD patients were classified as responders or nonresponders according to FEV1 improvement after 3 months of LABA/ICS treatment in fourteen referral hospitals in Korea. Exacerbation occurrence in these two subgroups was compared over a period of 1 yr. Eighty of the 137 COPD patients (58.4%) were classified as responders and 57 (41.6%) as nonresponders. Acute exacerbations occurred in 25 patients (31.3%) in the responder group and in 26 patients (45.6%) in the nonresponder group (P=0.086). FEV1 improvement after LABA/ICS treatment was a significant prognostic factor for fewer acute exacerbations in a multivariate Cox proportional hazard model adjusted for age, sex, FEV1, smoking history, 6 min walk distance, body mass index, exacerbation history in the previous year, and dyspnea scale.Three-month treatment response to LABA/ICS might be a prognostic factor for the occurrence of acute exacerbation in COPD patients.
Adrenal Cortex Hormones/*therapeutic use ; Adrenergic beta-2 Receptor Agonists/*therapeutic use ; Bronchodilator Agents/*therapeutic use ; Budesonide/therapeutic use ; Drug Therapy, Combination ; Female ; Fluticasone/therapeutic use ; Forced Expiratory Volume/drug effects/*physiology ; Formoterol Fumarate/therapeutic use ; Humans ; Male ; Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology ; Recurrence ; Republic of Korea ; Salmeterol Xinafoate/therapeutic use ; Smoking ; Spirometry ; Treatment Outcome

No abstract available.
Beclomethasone* ; Budesonide* ; Hydrocortisone*

PURPOSE: To evaluate the effect f nebulized budensonide and intramuscular dexamethasone in relieving laryngeal obstruction of croup. METHODS: Forty patients with moderate croup (croup scores of 3 to 7 out of 17) were randomly assigned to budesonide group [1 mg(2 ml) of nebulized budesonide, N=15], dexamethasone group [intramuscular dexamethasone(0.5 mg/kg) and nebulized saline, N=10] and control group(2 ml of nebulized saline, N=15). The changes of croup scores, heart rate, respiratory rate, and arterial oxygen saturation(SaO2) were observed at post-treatment of 2, 24, 36 and 48 hours. The duration of admission and the rates of improvement to the croup score of < or = 1 at the post-treatments were compared. RESULTS: Croup scores at 12, 24 and 36 hours post treatments were 1.7+/-0.8, 1.1+/-0.7 and 0.8+/-0.7 in budensonide group and 2.2+/-0.7, 1.2+/-0.8 and 1.0+/-0.5 in dexamethasone group respectively, which were significantly lower rate, and SaO2 were not significantly different among the three groups. Improved rates to croup score of <1 in budesonide group at post-treatments of 12, 24, and 36 jpirs were 53%, 73% and 87%, which were significantly higher than 0%, 13%, and 47% in control group (p<0.05). Improved rate to croup score of < or = 1 in dexamethasone group was 60^ which was significantly hgier than 13% in control group only at post-treatment of 24 hours (p<0.05). CONCLUSION: Nebulized budesonide and intramusculan dexamethasone are both effective in reducing obstructive symptoms in patients with moderate croup. The effect of nebulized budesonide was more rapid than that of intramuscular dexamethasone.
Budesonide* ; Croup ; Dexamethasone* ; Heart Rate ; Humans ; Oxygen ; Respiratory Rate

The aims of this study are to compare the efficacy and side effects of intranasal budesonide as a dry powder and as a freonpropelled pressurized aerosol in the treatment of perennial allergic rhinitis and to assess the difference in compliance with the powder and aerosol. The study design was a randomized, double-blind crossover between two treatment groups over a six-week period. Twelve patients with symptomatic perennial allergic rhinitis received 400 microgram of intranasal budesonide administered daily as two puffs/nostril/day of the drug delivered by a freon-propelled aerosol for the first three weeks and as one inhalation/nostril/day of the pure drug powder for the next three weeks. Fourteen adults with allergic rhinitis received the drug in the reverse sequence. Patients recorded daily symptoms on diaries, and, at each clinic visit, adverse effects were recorded. Compliance with the powder and with the aerosol was also evaluated. During the six weeks, there were significant improvements in symptoms in both treatment groups, and the differences in efficacy and compliance with the medication between the two groups were not significant. Adverse effects included headaches, epistaxis, and nasal dryness ; however, they were not serious and equally distributed in the two groups. We conclude that powder and aerosolized budesonide improve the symptoms of perennial allergic rhinitis significantly with little difference in efficacy, side effects, and preference.
Adult ; Ambulatory Care ; Budesonide* ; Compliance ; Epistaxis ; Headache ; Humans ; Rhinitis*

The aims of this study are to compare the efficacy and side effects of intranasal budesonide as a dry powder and as a freonpropelled pressurized aerosol in the treatment of perennial allergic rhinitis and to assess the difference in compliance with the powder and aerosol. The study design was a randomized, double-blind crossover between two treatment groups over a six-week period. Twelve patients with symptomatic perennial allergic rhinitis received 400 microgram of intranasal budesonide administered daily as two puffs/nostril/day of the drug delivered by a freon-propelled aerosol for the first three weeks and as one inhalation/nostril/day of the pure drug powder for the next three weeks. Fourteen adults with allergic rhinitis received the drug in the reverse sequence. Patients recorded daily symptoms on diaries, and, at each clinic visit, adverse effects were recorded. Compliance with the powder and with the aerosol was also evaluated. During the six weeks, there were significant improvements in symptoms in both treatment groups, and the differences in efficacy and compliance with the medication between the two groups were not significant. Adverse effects included headaches, epistaxis, and nasal dryness ; however, they were not serious and equally distributed in the two groups. We conclude that powder and aerosolized budesonide improve the symptoms of perennial allergic rhinitis significantly with little difference in efficacy, side effects, and preference.
Adult ; Ambulatory Care ; Budesonide* ; Compliance ; Epistaxis ; Headache ; Humans ; Rhinitis*

PURPOSE: Cough-variant asthma (CVA) is a common cause of chronic cough in young children. Some children who have CVA eventually develop classic asthma. We evaluated the effect of inhaled corticosteroid and leukotriene receptor antagonist in young children who are suspected of having CVA. METHODS: Thirty-seven cough-variant asthma patients younger than 5-years-old were enrolled in this study. Fifteen were treated with pulmicort nebulization (500 micorgram, bid) for 4 weeks (Group A). Fourteen were treated with leukotriene receptor antagonist (Singulair, 4 mg) for 4 weeks (Group B). Eleven were treated with intermittent short-acting beta2-agonist nebulization (Group C). We evaluated the mean change of symptom score in night cough and sleep disturbance. RESULTS: There were no differences in age, sex, total IgE, total eosinophil count or duration of cough among the three groups. Group A and B showed significant improvement of night cough and sleep disturbance after treatment. (P< 0.05) In Group A and B, night cough was significantly improved after treatment more than in control. (P< 0.05) But improvements in sleep disturbance didn't have any signigicant differences between the three groups. (P= 1.0) CONCLUSION: Inhaled corticosteroid and leukotriene receptor antagonist are effective to control chronic cough in CVA children younger than 5-years-old.
Asthma* ; Budesonide ; Child ; Cough ; Eosinophils ; Humans ; Immunoglobulin E ; Receptors, Leukotriene*

Bronchodilator Agents ; therapeutic use ; Budesonide ; therapeutic use ; Humans ; Laryngitis ; drug therapy

Nedocromil sodium is an anti-inflammatory medication for the treatment of mild to moderate asthma. The most common side effect of the nedocromil sodium is an unpleasant and bitter taste. However it is rare, less than 3%, to stop the treatment because of this side effect. Other side effects includes cough, headache, throat irritation and nausea which are reported as mild and transient. A 7-year-old female had a severe headache and dizziness during the treatment of asthma with nedocromil sodium. The symptoms subsided after nedocromil sodium was replaced by budesonide. We experienced a case of a severe headache and dizziness due to nedocomil sodium that lead to withdraw of the nedocromil sodium.
Asthma ; Budesonide ; Child ; Cough ; Dizziness* ; Female ; Headache* ; Humans ; Nausea ; Nedocromil* ; Pharynx ; Sodium

OBJECTIVES: Budesonide nasal irrigation was introduced recently for postoperative management of patients with chronic rhinosinusitis. The safety and therapeutic effectiveness of this procedure is becoming accepted by many physicians. The objective of this study was to evaluate the efficacy of postoperative steroid irrigation in patients with chronic rhinosinusitis and asthma. METHODS: This prospective study involved 12 chronic rhinosinusitis patients with nasal polyps and asthma who received oral steroid treatment for recurring or worsening disease. The 22-item Sinonasal Outcomes Test (SNOT-22) and Lund-Kennedy endoscopy scores were checked before nasal budesonide irrigation, and 1, 2, 4, and 6 months after irrigation. We also calculated the total amount of oral steroids and inhaled steroids in the 6 months before irrigation and the 6 months after it. RESULTS: The mean SNOT-22 score improved from 30.8±14.4 before irrigation to 14.2±8.7 after 6 months of irrigation (P=0.030). The endoscopy score also improved from 7.4±4.7 before irrigation to 2.2±2.7 after 6 months (P<0.001). The total amount of oral steroid was decreased from 397.8±97.6 mg over the 6 months before irrigation to 72.7±99.7 mg over the 6 months after irrigation (P<0.001). CONCLUSION: Nasal irrigation with budesonide is an effective postoperative treatment for chronic rhinosinusitis with asthma, which recurs frequently, reducing the oral steroid intake.
Asthma* ; Budesonide* ; Endoscopy ; Humans ; Nasal Lavage* ; Nasal Polyps ; Prospective Studies ; Sinusitis ; Steroids